Neurological diseases drug development company Actinogen Medical, capitalised at $95 million on the ASX, has tapped Bell Potter and MA Moelis to find funding to ramp up patient trials for its flagship Alzheimer’s therapy.
Actinogen is led by the former chief medical officer of Principia Biopharma, which was acquired by Sanofi for $US3.68 billion in 2020.
Michele Mossop
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
